Items where authors include "Chantry, A.D."

Article

Tazzyman, S., Stewart, G.R., Yeomans, J. orcid.org/0000-0002-9546-3600 et al. (6 more authors) (2023) HSV1716 prevents myeloma cell regrowth when combined with bortezomib in vitro and significantly reduces systemic tumor growth in mouse models. Viruses, 15 (3). 603. ISSN 1999-4915

Andrews, R.E., Brown, J.E. orcid.org/0000-0003-4960-3032, Lawson, M.A. orcid.org/0000-0002-5446-923X et al. (1 more author) (2021) Myeloma bone disease : the osteoblast in the spotlight. Journal of Clinical Medicine, 10 (17). 3973.

Diaz-delCastillo, M., Andrews, R.E., Mandal, A. et al. (3 more authors) (2021) Bone pain in multiple myeloma (BPMM) — a protocol for a prospective, longitudinal, observational study. Cancers, 13 (7). 1596.

Kass-Iliyya, L., Snowden, J.A. orcid.org/0000-0001-6819-3476, Thorpe, A. et al. (5 more authors) (2021) Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. Journal of Neurology, 268 (1). pp. 265-275. ISSN 0340-5354

Crawford, L.J., Campbell, D.C., Morgan, J.J. et al. (10 more authors) (2020) The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene, 39 (27). pp. 5001-5014. ISSN 0950-9232

Green, A.C. orcid.org/0000-0002-0175-1485, Lath, D. orcid.org/0000-0001-5454-9419, Hudson, K. et al. (8 more authors) (2019) TGFβ inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model. Journal of Bone and Mineral Research, 34 (12). pp. 2311-2326. ISSN 0884-0431

Paton-Hough, J., Tazzyman, S., Evans, H. et al. (6 more authors) (2019) Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models. Journal of Bone and Mineral Research, 34 (5). pp. 783-796. ISSN 0884-0431

Green, A.C. orcid.org/0000-0002-0175-1485, Rudolph-Stringer, V., Chantry, A.D. et al. (2 more authors) (2019) Mesenchymal lineage cells and their importance in B lymphocyte niches. Bone, 119. pp. 42-56. ISSN 8756-3282

Lath, D.L. orcid.org/0000-0001-5454-9419, Buckle, C.H., Evans, H.R. et al. (4 more authors) (2018) ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS One, 13 (6). e0199517. ISSN 1932-6203

Ring, E.S., Lawson, M.A., Snowden, J.A. et al. (2 more authors) (2018) New agents in the Treatment of Myeloma Bone Disease. Calcified Tissue International, 102 (2). pp. 196-209. ISSN 0171-967X

Chinnaiya, K., Lawson, M.A. orcid.org/0000-0002-5446-923X, Thomas, S. orcid.org/0000-0002-0027-0815 et al. (8 more authors) (2017) Low-dose methotrexate in myeloproliferative neoplasm models. Haematologica, 102 (6). 165738. ISSN 0390-6078

Lawson, M.A. orcid.org/0000-0002-5446-923X, Ebetino, F.H., Mazur, A. et al. (14 more authors) (2017) The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). Journal of Bone and Mineral Research, 32 (9). pp. 1860-1869. ISSN 0884-0431

Lawson, M.A., Paton-Hough, J.M., Evans, H.R. et al. (5 more authors) (2015) NOD/SCID-GAMMA Mice Are an Ideal Strain to Assess the Efficacy of Therapeutic Agents Used in the Treatment of Myeloma Bone Disease. PLOS ONE, 10 (3). e0119546. ISSN 1932-6203

Vitovski, S., Chantry, A.D., Lawson, M.A. et al. (1 more author) (2012) Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo. PLoS ONE, 7 (5). e35830. ISSN 1932-6203